Pasadena, CANCT05452941Now EnrollingIRB Ready

Pneumonia Clinical Trial in Pasadena, CA

Access cutting-edge pneumonia treatment through this clinical trial at a research site in Pasadena. Study-provided care at no cost to qualified participants.

Sponsored by Pfizer

Quick Self-Assessment

See if you qualify for this Pasadena location

Preparing your pre-screening questions…

Expert Care in Pasadena

Access pneumonia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pneumonia treatment provided free

Apply for This Pasadena Location

Check if you qualify for this pneumonia clinical trial in Pasadena, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pasadena

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pasadena site if eligible
  4. 4Begin participation

About This Pneumonia Study in Pasadena

The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 20vPnC vaccine. This study is seeking participants who: * are male or female ≥65 years of age. * are hospitalized with physician suspicion of community acquired pneumonia (CAP). * have pneumonia confirmed with imaging like a chest x-ray Participants will be asked to provide demographic and medical history information, and to provide a urine sample that will be used to test for pneumonia caused by specific strains of a bacteria called Streptococcus pneumoniae. We will compare the proportion of participants who have pneumonia caused by specific strains of the bacteria Streptococcus pneumoniae and were previously vaccinated with 20vPnC with the proportion of participants who have pneumonia caused by something other than vaccine type Streptococcus pneumoniae and have been vaccinated with 20vPnC. Participants will actively take part in the study for about 1-2 days. Information on participant's illness and hospitalization details will be collected through day 30 of their hospitalization through medical chart review.

Sponsor: Pfizer

Who Can Participate

Inclusion Criteria

Male or female participants ≥65 years of age.
Hospitalized participant with physician clinical suspicion of CAP with the presence of ≥2 of the following 10 clinical signs or symptoms:
fever (oral temperature \>38.0°C/100.4°F or tympanic temperature \>38.5°C/101.2°F),
hypothermia (\<35.5°C/95.9°F measured by a healthcare provider)
chills or rigors,
pleuritic chest pain,
new or worsening cough,
sputum production,
dyspnea (shortness of breath),
tachypnea (respiratory rate \>20/min),
malaise, or
abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation including dullness on percussion, bronchial breath sounds, or egophony).
Has a radiographic finding that is consistent with pneumonia (e.g., pleural effusion, increased pulmonary density due to infection, the presence of alveolar infiltrates \[multi-lobar, lobar, or segmental\] containing air bronchograms).
Capable of giving signed informed consent

Exclusion Criteria

Any participant who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at the study site, another transferring hospital, or a combination of these).
Received any pneumococcal vaccine ≤30 days prior to enrollment.
Unable to provide urine specimen (e.g. anuric).
Previous enrollment in the study within the past 30 days.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pasadena?

Yes, this clinical trial (NCT05452941) has an active research site in Pasadena, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pneumonia Treatment Options in Pasadena, CA

If you're searching for pneumonia treatment options in Pasadena, CA, this clinical trial (NCT05452941) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pasadena research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pneumonia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pneumonia clinical trials near you to find additional studies recruiting in your area.

More Pneumonia Trials in Pasadena, CA

See all pneumonia clinical trials recruiting in Pasadena — not just this study.

Browse Pneumonia Trials in Pasadena

Ready to Join in Pasadena?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pasadena, CA